ScoreWhy is Panacea Biotec Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Net Sales has grown by an annual rate of 0.80% and Operating profit at -250.53% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.48
2
Flat results in Dec 25
- CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 81.61 cr
- NON-OPERATING INCOME(Q) is 61.29 % of Profit Before Tax (PBT)
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -20.86%, its profits have fallen by -139.9%
4
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
5
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 0.10% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -20.86% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Panacea Biotec for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Panacea Biotec
-21.21%
-0.39
52.83%
Sensex
-11.86%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
1.50%
EBIT Growth (5y)
-233.29%
EBIT to Interest (avg)
-10.27
Debt to EBITDA (avg)
2.73
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
0.72
Tax Ratio
13.90%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.56%
ROCE (avg)
-12.06%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
36
Price to Book Value
2.54
EV to EBIT
-68.23
EV to EBITDA
946.49
EV to Capital Employed
2.64
EV to Sales
3.08
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.81%
ROE (Latest)
-2.31%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
PAT(9M)
Higher at Rs 0.74 Cr
NET SALES(Q)
Highest at Rs 199.57 cr
-2What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 64.37 cr
NON-OPERATING INCOME(Q)
is 510.84 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Panacea Biotec
Net Sales - Quarterly
Highest at Rs 199.57 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Nine Monthly
Higher at Rs 0.74 Cr
than preceding 12 month period ended Jun 2026 of Rs -47.25 crMOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
PAT (Rs Cr)
Here's what is not working for Panacea Biotec
Non Operating Income - Quarterly
is 510.84 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 64.37 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
